Jose joined Roche Pharma Research Early Development (PRED), Oncology in May 2013 as Senior Translational Medicine Leader located at Roche Innovation Center Zurich.
He is currently collaborating with academic experienced immunotherapy Institutions in US and EU regarding the entry into human and early development in solid tumors of the first two T-cell bispecific antibodies from the PRED T-cell engager platform.
Recently, he has initiated as well the phase Ib trial of CEA CD3 TCB in combination with atezolizumab in solid tumors expressing CEA.
Jose has previously moved into clinical trials in solid tumors, the first targeted cytokine from the PRED antigen targeted cytokine platform.
Jose graduated as MD at the University of Oviedo (Spain), and then completed the board certificate training in Internal Medicine at the University of Cape Town and the Complutense University (Madrid, Spain) where he also received his master degree in Pharmaceutical Medicine.
Jose worked as internal medicine physician at the San Carlos Clinical Hospital at Complutense University of Madrid.
Prior to join Roche, Jose hold two executive director positions at Novartis Oncology translational medicine where he was the global clinical lead for 4 TKI programs from late discovery to POC and more recently at Bristol-Myers Squibb as head of the European Oncology CR&D group and appointed core member of the Oncology Disease Strategic Team. Dr Saro has contributed to very innovative immunotherapy programs including Ipilimumab, anti PD-1, anti-PDL-1 and elotuzumab studies.
Focus at Roche, translational medicine on immunotherapy of cancer, development of biomarker to assess immunotherapies and immunotherapy NME (new molecular entities) combination trials. Jose is member of the Scientific Committee of the Immunotherapy of Cancer Congress (ITOC). Is also a member of ASCO, AACR, SITC and ESMO.